SG11201701040XA - Chimeric antigen receptors - Google Patents
Chimeric antigen receptorsInfo
- Publication number
- SG11201701040XA SG11201701040XA SG11201701040XA SG11201701040XA SG11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA
- Authority
- SG
- Singapore
- Prior art keywords
- chimeric antigen
- antigen receptors
- receptors
- chimeric
- antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Husbandry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052901P | 2014-09-19 | 2014-09-19 | |
| US201462052947P | 2014-09-19 | 2014-09-19 | |
| US201462076836P | 2014-11-07 | 2014-11-07 | |
| US201462094603P | 2014-12-19 | 2014-12-19 | |
| US201562167650P | 2015-05-28 | 2015-05-28 | |
| PCT/US2015/050975 WO2016044745A1 (en) | 2014-09-19 | 2015-09-18 | Chimeric antigen receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701040XA true SG11201701040XA (en) | 2017-03-30 |
Family
ID=54261082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701040XA SG11201701040XA (en) | 2014-09-19 | 2015-09-18 | Chimeric antigen receptors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160081314A1 (en) |
| EP (1) | EP3193592A1 (en) |
| JP (1) | JP2017529841A (en) |
| KR (1) | KR20170083534A (en) |
| CN (1) | CN107072184A (en) |
| AU (1) | AU2015317370A1 (en) |
| BR (1) | BR112017005245A2 (en) |
| CA (1) | CA2959428A1 (en) |
| IL (1) | IL250536A0 (en) |
| MX (1) | MX2017003640A (en) |
| RU (1) | RU2017113134A (en) |
| SG (1) | SG11201701040XA (en) |
| WO (1) | WO2016044745A1 (en) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150064153A1 (en) | 2013-03-15 | 2015-03-05 | The Trustees Of Princeton University | High efficiency microfluidic purification of stem cells to improve transplants |
| CN105264127B (en) | 2013-03-15 | 2019-04-09 | Gpb科学有限责任公司 | The on piece microfluidic process of particle |
| CA2942831A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Princeton University | Methods and devices for high throughput purification |
| KR102088082B1 (en) * | 2014-03-05 | 2020-03-11 | 유씨엘 비즈니스 리미티드 | Chimeric antigen receptor(car) with antigen binding domains to the t cell receptor beta constant region |
| US11982673B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| FR3029449B1 (en) * | 2014-12-03 | 2017-10-13 | Pole De Plasturgie De Lest | MOLDING DEVICE FOR MANUFACTURING COMPOSITE MATERIAL PARTS FROM LIQUID POLYMER RESIN. |
| WO2016100819A1 (en) * | 2014-12-19 | 2016-06-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| SG11201708706YA (en) | 2015-05-06 | 2017-11-29 | Snipr Tech Ltd | Altering microbial populations & modifying microbiota |
| US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
| WO2017062451A1 (en) * | 2015-10-05 | 2017-04-13 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| ES2883116T3 (en) | 2015-10-05 | 2021-12-07 | Prec Biosciences Inc | Meganucleases Engineered with Recognition Sequences Found in the Human T Cell Receptor Alpha Constant Region Gene |
| KR102427334B1 (en) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | Chimeric antigens and T cell receptors and methods of use |
| CU20180120A7 (en) | 2016-04-01 | 2019-05-03 | Kite Pharma Inc | BCMA UNION MOLECULES |
| MA43603A1 (en) | 2016-04-01 | 2019-03-29 | Amgen Inc | Chimeric receptors and methods of use |
| WO2017180989A2 (en) | 2016-04-15 | 2017-10-19 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| SG11201810757YA (en) * | 2016-06-03 | 2018-12-28 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| US20190297861A1 (en) * | 2016-07-12 | 2019-10-03 | Kymab Limited | Animals, cells, ligands, polypeptides & methods |
| SG11201901528RA (en) * | 2016-08-23 | 2019-03-28 | Univ California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| WO2018075586A1 (en) * | 2016-10-18 | 2018-04-26 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
| AU2017366739B2 (en) | 2016-12-02 | 2023-11-23 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | Adam9-binding molecules, and methods of use thereof |
| EP3579877A4 (en) * | 2017-02-09 | 2020-12-09 | The Regents of The University of California | T-CELL CHIMERA ANTIGEN RECEPTORS AND METHOD OF USING THEREOF |
| US20180280437A1 (en) | 2017-03-13 | 2018-10-04 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| JP7305549B2 (en) * | 2017-04-05 | 2023-07-10 | エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド | HUMANIZED ANTI-TPBG ANTIBODY AND METHOD FOR MANUFACTURE THEREOF, CONJUGATE AND USES THEREOF |
| JOP20180042A1 (en) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | Humanized Antigen-Binding Domains and Methods of Use |
| EP3645038A1 (en) | 2017-06-30 | 2020-05-06 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| MX2020001177A (en) | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Crispr reporter non-human animals and uses thereof. |
| KR102712142B1 (en) | 2017-07-31 | 2024-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
| US10844353B2 (en) | 2017-09-01 | 2020-11-24 | Gpb Scientific, Inc. | Methods for preparing therapeutically active cells using microfluidics |
| MX2020003144A (en) | 2017-09-22 | 2020-07-28 | Wuxi Biologics Ireland Ltd | Novel bispecific cd3/cd19 polypeptide complexes. |
| CN111133003B (en) * | 2017-09-22 | 2024-01-12 | 上海药明生物技术有限公司 | Novel bispecific peptide complex |
| MX394999B (en) | 2017-09-29 | 2025-03-24 | Regeneron Pharma | Non-human animals comprising a humanized |
| IL305485A (en) | 2017-10-27 | 2023-10-01 | Univ California | Targeted replacement of endogenous T cell receptors |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| ES2973937T3 (en) | 2017-11-30 | 2024-06-25 | Regeneron Pharma | Rats comprising a humanized TRKB locus |
| EP3752599A1 (en) | 2018-02-16 | 2020-12-23 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| JP7334178B2 (en) | 2018-03-19 | 2023-08-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Transcriptional modulation in animals using the CRISPR/Cas system |
| LT3772927T (en) * | 2018-03-24 | 2025-02-10 | Regeneron Pharmaceuticals, Inc. | GENETIC MODIFIED MICE OR RATS FOR PRODUCTION OF THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND USE THEREOF |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CN108424931A (en) * | 2018-03-29 | 2018-08-21 | 内蒙古大学 | The method that CRISPR/Cas9 technologies mediate goat VEGF Gene targetings |
| AU2019252527B2 (en) | 2018-04-12 | 2024-02-22 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| CA3177829A1 (en) | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
| CN113272319A (en) * | 2018-12-27 | 2021-08-17 | 国立大学法人京都大学 | Variants of T cell receptors |
| CA3133360A1 (en) | 2019-04-04 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| EP3801011A1 (en) | 2019-06-04 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| EP3796776A1 (en) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
| PH12021553306A1 (en) * | 2019-07-03 | 2022-08-01 | Regeneron Pharma | Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof |
| WO2021011907A1 (en) | 2019-07-18 | 2021-01-21 | Gpb Scientific, Inc. | Ordered processing of blood products to produce therapeutically active cells |
| CN115209996A (en) | 2019-12-28 | 2022-10-18 | Gpb科学有限公司 | Microfluidic cartridge for processing particles and cells |
| CA3169272A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| CN111320703A (en) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | Chimeric antigen receptor targeting CD22 and application thereof |
| WO2021190580A1 (en) * | 2020-03-26 | 2021-09-30 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific polypeptide complexes, compositions, and methods of preparation and use |
| CN114746152A (en) * | 2020-08-23 | 2022-07-12 | 应用干细胞有限公司 | HLA-F modified cells and methods |
| WO2022236049A1 (en) * | 2021-05-07 | 2022-11-10 | Senti Biosciences, Inc. | Chimeric antigen receptors and methods of use |
| EP4215042A1 (en) * | 2022-01-21 | 2023-07-26 | Max-Delbrück-Centrum für Molekulare Medizin | A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN116138212B (en) * | 2023-01-11 | 2024-03-05 | 江苏省中医院 | Method for preparing cytokine release syndrome mouse model and application |
| CN118460446B (en) * | 2024-07-12 | 2024-11-15 | 内蒙古自治区农牧业科学院 | A mycoplasma mutant strain and its preparation method and application |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | CHANGED ANTIBODIES. |
| JPS6463394A (en) * | 1987-09-04 | 1989-03-09 | Kyowa Hakko Kogyo Kk | Novel chimera polypeptide |
| IL86278A (en) * | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| EP0710719B1 (en) | 1990-01-12 | 2007-03-14 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6045796A (en) | 1992-12-17 | 2000-04-04 | Anergen, Inc. | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US7001614B2 (en) | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
| US7112338B2 (en) | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | Mhc-peptide complex binding ligands |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| US8663622B2 (en) | 2002-12-16 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant vaccine viruses expressing IL-15 and methods using the same |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| US8218805B2 (en) | 2003-10-11 | 2012-07-10 | Charles Hornback | Wireless speaker system for use with ceiling fans |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| EP1709081B1 (en) | 2004-01-16 | 2011-04-06 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| EP1773383B1 (en) | 2004-05-27 | 2012-09-12 | Jon A. Weidanz | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| ES2463476T3 (en) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Method to generate a homozygous mouse for a genetic modification |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | Engineering fc antibody regions to confer effector function |
| US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| AU2006204791A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc | Antibodies and Fc fusion proteins with altered immunogenicity |
| WO2007022520A2 (en) | 2005-08-19 | 2007-02-22 | Cerus Corporation | Antibody-mediated enhancement of immune response |
| EP4332227A1 (en) | 2005-08-23 | 2024-03-06 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| JP5514539B2 (en) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| CA2702586C (en) | 2007-10-18 | 2017-08-01 | Bn Immunotherapeutics Inc. | Use of mva to treat prostate cancer |
| US8225343B2 (en) | 2008-01-11 | 2012-07-17 | Sony Computer Entertainment America Llc | Gesture cataloging and recognition |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| PT2501817E (en) | 2010-02-08 | 2015-11-04 | Regeneron Pharma | Common light chain mouse |
| AU2011235569B2 (en) | 2010-03-29 | 2016-06-30 | Zymeworks Bc Inc. | Antibodies with enhanced or suppressed effector function |
| EP2568049B1 (en) | 2010-06-22 | 2016-04-13 | Regeneron Pharmaceuticals, Inc. | Mice expressing an immunoglobulin hybrid light chain with a human variable region |
| US8539547B2 (en) | 2010-08-18 | 2013-09-17 | Certes Networks, Inc. | Policy selector representation for fast retrieval |
| HUE046081T2 (en) | 2011-02-25 | 2020-01-28 | Regeneron Pharma | Adam6 mouse |
| JP5893258B2 (en) | 2011-03-31 | 2016-03-23 | フェリカネットワークス株式会社 | Information processing apparatus and method, and program |
| BR112014009941B1 (en) | 2011-10-28 | 2022-11-29 | Regeneron Pharmaceuticals, Inc | METHODS FOR PRODUCING A GENETICALLY MODIFIED RODENT EMBRYONIC STEM CELL(S) |
| CN107858332A (en) * | 2011-10-28 | 2018-03-30 | 瑞泽恩制药公司 | φt cell receptor genetic modification mouse |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| EP4311833A3 (en) | 2011-10-28 | 2024-05-01 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| CN109897103B (en) | 2011-11-04 | 2024-05-17 | 酵活英属哥伦比亚有限公司 | Stable heterodimeric antibody design with mutations in the Fc domain |
| US9547499B2 (en) | 2011-12-09 | 2017-01-17 | Microsoft Technology Licensing, Llc | Device configuration with cached pre-assembled driver state |
| WO2013126726A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JP5920830B2 (en) | 2012-09-28 | 2016-05-18 | シスメックス株式会社 | Sample preparation device and cell analysis device |
| ES2736052T3 (en) | 2013-02-20 | 2019-12-23 | Regeneron Pharma | Mice expressing humanized T-cell co-receptors |
| RS57582B1 (en) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
| ES2697248T3 (en) | 2013-02-22 | 2019-01-22 | Regeneron Pharma | Mice expressing major human histocompatibility complex |
-
2015
- 2015-09-18 EP EP15775854.1A patent/EP3193592A1/en not_active Withdrawn
- 2015-09-18 KR KR1020177010023A patent/KR20170083534A/en not_active Withdrawn
- 2015-09-18 CN CN201580050602.0A patent/CN107072184A/en active Pending
- 2015-09-18 CA CA2959428A patent/CA2959428A1/en not_active Abandoned
- 2015-09-18 US US14/858,597 patent/US20160081314A1/en not_active Abandoned
- 2015-09-18 RU RU2017113134A patent/RU2017113134A/en not_active Application Discontinuation
- 2015-09-18 WO PCT/US2015/050975 patent/WO2016044745A1/en active Application Filing
- 2015-09-18 SG SG11201701040XA patent/SG11201701040XA/en unknown
- 2015-09-18 AU AU2015317370A patent/AU2015317370A1/en not_active Abandoned
- 2015-09-18 JP JP2017515087A patent/JP2017529841A/en active Pending
- 2015-09-18 BR BR112017005245A patent/BR112017005245A2/en not_active Application Discontinuation
- 2015-09-18 MX MX2017003640A patent/MX2017003640A/en unknown
-
2017
- 2017-02-09 IL IL250536A patent/IL250536A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2959428A1 (en) | 2016-03-24 |
| IL250536A0 (en) | 2017-03-30 |
| KR20170083534A (en) | 2017-07-18 |
| AU2015317370A1 (en) | 2017-03-23 |
| BR112017005245A2 (en) | 2017-12-12 |
| RU2017113134A (en) | 2018-10-19 |
| EP3193592A1 (en) | 2017-07-26 |
| MX2017003640A (en) | 2017-10-31 |
| JP2017529841A (en) | 2017-10-12 |
| WO2016044745A1 (en) | 2016-03-24 |
| CN107072184A (en) | 2017-08-18 |
| US20160081314A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291292A (en) | Chimeric antigen receptors targeting cd-19 | |
| IL250536A0 (en) | Chimeric antigen receptors | |
| IL251030A0 (en) | Chimeric antigen receptors | |
| ZA201704059B (en) | Bcma chimeric antigen receptors | |
| IL254254B (en) | Chimeric antigen receptor | |
| ZA201700730B (en) | Bcma chimeric antigen receptors | |
| IL258527A (en) | Anti-cd30 chimeric antigen receptors | |
| SG11201606790XA (en) | Chimeric antigen receptor | |
| GB201617290D0 (en) | Novel chimeric antigen receptors | |
| EP3256496A4 (en) | Chimeric antigen receptors | |
| GB201503742D0 (en) | Chimeric antigen receptor | |
| PT3230310T (en) | Anti-cd70 chimeric antigen receptors | |
| HUE056735T2 (en) | Mnd promoter chimeric antigen receptors | |
| GB201411420D0 (en) | Antibody constructs | |
| GB201519900D0 (en) | Chimeric antigen receptor | |
| GB201409761D0 (en) | Chimeric antigen receptor | |
| GB201403481D0 (en) | Chimeric antigen receptor |